RNA Interference (RNAi)

RNA Interference (RNAi)

Global RNA Interference (RNAi) Market to Reach US$206.7 Billion by 2030

The global market for RNA Interference (RNAi) estimated at US$99.4 Billion in the year 2023, is expected to reach US$206.7 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2023-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 16.4% CAGR and reach US$118.1 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.6 Billion While China is Forecast to Grow at 17.3% CAGR

The RNA Interference (RNAi) market in the U.S. is estimated at US$25.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$59.5 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global RNA Interference (RNAi) Market - Key Trends and Drivers Summarized

RNA interference (RNAi) is a vital biological process where RNA molecules inhibit gene expression, a mechanism discovered due to its role in silencing genes by neutralizing targeted messenger RNA (mRNA) molecules. RNA, essential in the coding, decoding, regulation, and expression of genes, facilitates RNAi through two types of small RNA molecules: small interfering RNA (siRNA) and microRNA (miRNA), each about 22 nucleotides long. SiRNAs are engineered to specifically target and silence particular mRNAs, preventing protein production, and are processed from double-stranded RNA, which is cleaved and transported into the cytoplasm. Conversely, miRNAs, originating from single-stranded RNA that folds into hairpin structures, broadly regulate protein synthesis. This discovery, which brought Andrew Fire and Craig Mello the Nobel Prize in 2006, underscored RNAi as a natural defense against genomic parasites and a crucial regulator in protein synthesis.

The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in "knockdown" experiments, where protein expression is reduced to investigate function without altering the genome. RNAi`s ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.

RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi`s specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi`s application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.

Select Competitors (Total 12 Featured) -

• Alnylam Pharmaceuticals, Inc.
• Benitec BioPharma
• Ionis Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Qiagen, Inc.
• Quark Pharmaceuticals, Inc.
• Silence Therapeutics PLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.